JPRN-UMIN000012188尚未招募未知
Establishment of a proper use of ranibizumab for the macular edema in retinal vein occlusion - Establishment of a proper use of ranibizumab for RVO
Departmant of opthalmology,Kansai Medical University0 个研究点目标入组 50 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 40years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A history of cerebral hemorrhage and cerebral infection.
研究者
相似试验
进行中（未招募）
1 期
The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using LucentisCorneal neovesselsEUCTR2010-018673-37-GBniversity of Nottingham6
进行中（未招募）
1 期
A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes. - Ranibizumab for inflammatory choroidal neovascular membranesEUCTR2008-007476-19-GBniversity Hospitals Bristol NHS Trust15
招募中
1 期
ong-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion (CoRaLa II trial)Macular edema due to central retinal vein occlusionMedDRA version: 20.0Level: LLTClassification code: 10007972Term: Central retinal vein occlusion Class: 10015919MedDRA version: 20.0Level: LLTClassification code: 10054467Term: Macular edema Class: 10015919CTIS2023-507816-11-00Justus-Liebig-Universitaet Giessen110
尚未招募
不适用
To Evaluate Whether a Repeat Injection of Ranibizumab at 6 Weeks can Reduce the Rate of Disease Reactivation in Aggressive Retinopathy of Prematurity (AROP)CTRI/2022/07/044475Janani Shishu Suraksha Karyakram
尚未招募
不适用
The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to AfliberceptJPRN-UMIN000012724Department of Ophthalmology, Kagawa university faculty of medicine30